Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 428 across all filing types
Latest filing 2021-03-08 Regulatory Filings
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated March 8, 2021, announcing that Vaishali Pharma Limited has been awarded two tenders for supplying surgical and pharmaceutical products to Vanuatu Islands and Samoa Islands. It is addressed to the National Stock Exchange of India and includes a request to take the information on record. The content focuses on business development and marketing achievements rather than financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or detailed report content. The document is a corporate announcement about new business contracts, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 6933 characters, which is sufficient for a detailed announcement but does not contain financial or report data to classify as a financial report or other specific category.
2021-03-08 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document contains only references to omitted pictures and has a very short length of 326 characters. There is no textual content indicating any report, announcement, or detailed information. Given the extremely limited content and absence of substantive information, this document does not represent a full report or detailed filing. It is likely a placeholder or a minimal announcement. According to the MENU VS MEAL RULE, such short documents with no substantive content are best classified as Regulatory Filings (RNS) as a fallback category.
2021-01-20 English
Press Release
Regulatory Filings
2021-01-20 English
Financial Result Updates
Regulatory Filings
2021-01-19 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data including revenue, expenses, profit before tax, net profit, earnings per share, and other comprehensive income for quarterly and nine-month periods ending December 31, 2020. The presence of unaudited financial results for specific quarters and nine-month periods indicates this is a periodic financial report shorter than a full fiscal year. The document length is under 5,000 characters but contains substantive financial data, not just an announcement or certification. There is no indication that this is an annual report, audit report, or earnings release summary. The detailed financial tables and period coverage align with an Interim / Quarterly Report (IR). 9M 2020
2021-01-19 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a press release announcing that Vaishali Pharma Limited has received a bulk order worth INR 320 million for PPE kits and other pharmaceutical products. It contains no financial statements, no detailed financial performance data, no regulatory filing references, or any mention of shareholder meetings, voting results, or management changes. The content focuses on business updates and marketing achievements rather than financial reporting or regulatory compliance. The document length is 6940 characters, which is sufficient for a press release but does not contain the depth or structure of an earnings release or annual/interim report. Therefore, the document is best classified as a Capital/Financing Update (CAP) since it relates to a significant business order impacting company operations and potential revenue growth, but it is not a formal financial report or regulatory filing.
2021-01-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.